B Escudier

Author PubWeight™ 88.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998 4.93
2 Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009 2.12
3 Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2010 2.11
4 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002 2.03
5 Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol 2011 2.03
6 Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010 1.91
7 Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 1997 1.77
8 Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010 1.65
9 Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013 1.65
10 Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000 1.59
11 Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009 1.57
12 Heat and moisture exchanger vs heated humidifier during long-term mechanical ventilation. A prospective randomized study. Chest 1991 1.43
13 High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007 1.35
14 Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011 1.34
15 Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2011 1.29
16 Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013 1.24
17 Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003 1.21
18 Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 1998 1.18
19 First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008 1.18
20 Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2009 1.15
21 Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 2010 1.13
22 Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 1992 1.13
23 Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2009 1.09
24 Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit. Infect Control Hosp Epidemiol 1990 1.07
25 Exosomes for cancer immunotherapy. Ann Oncol 2004 1.03
26 Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2009 0.98
27 Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996 0.97
28 Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000 0.97
29 Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: Which is the best predictor? Do multiple assessment times improve the predictive value? Crit Care Med 1998 0.96
30 Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 2011 0.96
31 Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures. Eur J Cancer 1997 0.94
32 The postchemotherapy PSA surge syndrome. Ann Oncol 2008 0.92
33 Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013 0.91
34 Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis. Lab Invest 1999 0.90
35 Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene 2011 0.90
36 Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 2000 0.89
37 Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol 2013 0.88
38 Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003 0.88
39 Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol 1998 0.88
40 Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer 2012 0.87
41 In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 1996 0.87
42 [CCAFU Recommendations 2013: Renal cancer]. Prog Urol 2013 0.87
43 Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002 0.87
44 [Eruptive nevi associated with sorafenib treatment]. Ann Dermatol Venereol 2008 0.86
45 Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995 0.86
46 Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000 0.85
47 Early tracheotomy in neutropenic, mechanically ventilated patients: rationale and results of a pilot study. Support Care Cancer 1995 0.85
48 Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 2013 0.85
49 Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999 0.85
50 The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 1994 0.84
51 In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res 1995 0.84
52 Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 2010 0.83
53 Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. J Am Coll Surg 1995 0.82
54 Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer 2013 0.81
55 Esophageal squamous cell carcinoma: the specific limited place of surgery defined by a prospective multivariate study of prognostic factors after surgical approach. Eur J Surg Oncol 1992 0.81
56 [Recommendations Onco-Urology 2010: Kidney cancer]. Prog Urol 2010 0.81
57 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 1996 0.80
58 Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009 0.80
59 Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Response Mod 1990 0.80
60 A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol 2000 0.80
61 Should the number of pulmonary metastases influence the surgical decision? Eur J Cardiothorac Surg 1997 0.80
62 Safety of tracheotomy in neutropenic patients: a retrospective study of 26 consecutive cases. Intensive Care Med 1995 0.80
63 Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999 0.80
64 Wegener's granulomatosis presenting as diffuse pulmonary hemorrhage. Intensive Care Med 1991 0.80
65 Acute myocardiotoxicity during 5-fluorouracil therapy. Intensive Care Med 1990 0.79
66 The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Netw 2005 0.79
67 Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. Int J Cancer 1993 0.79
68 Recombinant interferon-alpha efficacy in relapsed adult nephroblastoma: a case report. J Urol 1994 0.79
69 Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer 2012 0.79
70 Overrepresentation of 7q31 and 17q in renal cell carcinomas. Genes Chromosomes Cancer 1998 0.78
71 [Epidermoid cancer of the esophagus: is the combination of chemotherapy then surgery beneficial?]. Bull Cancer 1989 0.78
72 Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J Immunother 1999 0.78
73 Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). J Immunother 2000 0.78
74 T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapy. J Immunother Emphasis Tumor Immunol 1994 0.78
75 Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. Int J Cancer 1993 0.77
76 Novel and bone-targeted agents for CRPC. Ann Oncol 2012 0.77
77 T-cell receptor repertoire in neuroblastoma patients. Cancer Res 1996 0.77
78 Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial. Eur Cytokine Netw 2001 0.77
79 Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2009 0.77
80 Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2015 0.76
81 T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines. Int J Cancer 1997 0.76
82 [What may be the waiting time between the diagnosis and surgical treatment of kidney cancer?]. Prog Urol 2008 0.75
83 Blood gas analysis in patients with hyperleucocytosis: validity of repeated measures on same sampling without ice? Leuk Res 1994 0.75
84 Lithium concentrations during cisplatin-based chemotherapy: evidence for renal interaction. Cancer Chemother Pharmacol 1995 0.75
85 Do bacteriuria and candiduria have predictive value in the diagnosis of postlaparotomy peritonitis? Clin Infect Dis 1994 0.75
86 Thrombotic microangiopathy associated with Streptococcus pneumoniae infection: role of renal biopsy. Clin Infect Dis 1995 0.75
87 [The place of laparoscopic nephrectomy in the elderly subject]. Prog Urol 2009 0.75
88 [Atypical cysts and cystic tumours of the kidney: histological, radiological and surgical considerations. Conclusions of the AFU 2007 forum]. Prog Urol 2008 0.75
89 Cellular and molecular immunology of an important regulatory cytokine. New York 9-12, November 1995. Eur Cytokine Netw 1996 0.75
90 [Bullous dermatosis with linear IgA deposits along the basement membrane during treatment with gamma interferon and interleukin-2]. Ann Dermatol Venereol 1990 0.75
91 [Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management]. Presse Med 1986 0.75
92 [Anastomotic fistula after gastrectomy. Diagnostic value of radiologic monitoring. Retrospective study of 123 gastrectomies]. Presse Med 1987 0.75
93 Studies on NK cell purification by negative selection in human peripheral blood. Biotherapy 1992 0.75
94 [A rare cause of digital arteritis with Raynaud's phenomenon and digital necrosis: virus B hepatitis. 3 cases]. Ann Med Interne (Paris) 1982 0.75
95 Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors. Ann Oncol 2011 0.75
96 [Leg aneurysm complicating bacterial endocarditis. 2 cases]. Presse Med 1983 0.75
97 "Spontaneous" regressions of a metastatic adenocarcinoma transmitted by a cadaver kidney graft: support for immunotherapy? Cancer Immunol Immunother 1994 0.75
98 [Reliability of the response rate in oncology: analysis of the causes for variation]. Bull Cancer 2000 0.75
99 [Targeted therapies: sequential and combined treatments]. Bull Cancer 2010 0.75
100 Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring. Int J Cancer 1994 0.75
101 [Cardiotoxicity of 5-fluorouracil. Apropos of a new case]. Arch Mal Coeur Vaiss 1985 0.75
102 Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases. Support Care Cancer 1994 0.75
103 [Pseudoparalysis induced by cancer chemotherapy (cis-platinum)]. Cah Anesthesiol 1985 0.75
104 [A multivariate prospective study of prognostic factors in 200 operated epidermoid cancers of the esophagus. Definition of patients for whom surgical resection was of benefit]. Gastroenterol Clin Biol 1993 0.75
105 Thalidomide and venous thrombosis. Ann Intern Med 2002 0.75
106 [Update on the different histological types of renal cell carcinoma and their specific treatment]. Prog Urol 2011 0.75
107 Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 1995 0.75
108 [Renal tolerability of cisplatin]. Rev Med Interne 1996 0.75
109 [Case report of kidney cancer from JOUM 2010]. Prog Urol 2011 0.75
110 [Do ablative treatments modify the management of kidney tumors in the elderly?]. Prog Urol 2009 0.75
111 [Tracheal rupture during intubation for general anesthesia]. Ann Fr Anesth Reanim 1986 0.75
112 [Anatomo-clinical conference at the Pitié-Salpêtrière. Polyarthritis, renal insufficiency and arterial hypertension in a 47-year-old woman]. Ann Med Interne (Paris) 1982 0.75
113 Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure. Am Heart J 1985 0.75
114 Contribution to the study of unconscious psychic mechanism in the anesthesiologist. Acta Anaesthesiol Belg 1984 0.75
115 [Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine]. Arch Mal Coeur Vaiss 1984 0.75
116 [Current role of lymph node dissection in renal cell carcinoma: review of the literature by the Oncology Committee of the French Association of Urology (CCAFU)]. Prog Urol 2012 0.75
117 [Cytokines and solid tumors]. Rev Prat 1993 0.75
118 In vivo activation of LAK cells during systemic IL-2 therapy. Eur Cytokine Netw 1991 0.75
119 [Cancer of the kidney in the adult]. Bull Cancer 1998 0.75
120 [Kidney cancer management in 2007: news and recommendations]. Prog Urol 2008 0.75
121 [Treatment of metastatic malignant insulinomas. 2 cases]. Presse Med 1995 0.75
122 [Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comité de cancérologie de l'Association française d'urologie (CCAFU)]. Prog Urol 2009 0.75
123 [Spontaneous bilateral chylothorax. Cure by a single puncture]. Presse Med 1983 0.75
124 Cerebral vasculitis after interleukin-2 therapy for renal cell carcinoma. J Immunother Emphasis Tumor Immunol 1995 0.75
125 [Renal cell carcinoma management and therapies in 2010]. Bull Cancer 2010 0.75
126 [Cancer immunotherapy: immunologic bases, reality and hopes]. Bull Cancer 1993 0.75
127 FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC. Ann Oncol 2010 0.75
128 [New drugs in metastatic castration-resistant prostate cancer]. Bull Cancer 2010 0.75
129 [How to prevent the tumor lysis syndrome]. Presse Med 1985 0.75
130 [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer]. Prog Urol 2010 0.75
131 Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study. Cancer Biother Radiopharm 1996 0.75
132 [Therapeutic strategy in metastatic renal cancer]. Rev Prat 1992 0.75
133 [Hyperuricemia resistant to urate oxidase. Efficacy of high doses]. Presse Med 1984 0.75